Robust chronic performance drives 8.4% growth for Indian pharma mkt in FY25

Quick Summary:

In March 2025, the segment’s moving annual turnover (MAT) — which represents the previous 12 months’ turnover — stood at Rs 576 crore, of which tirzepatide accounted for Rs 1.4 crore within a month of its launch.

Among the well-performing therapies, the cardiac segment saw a 10.8 per cent value growth, followed by gastrointestinal and anti-diabetic segments at 10.2 per cent and 8 per cent, respectively.

Pharmarack added that the IPM also reported a positive 1.8 per cent unit growth in March 2025.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: India

Topics: Top pharma brands India FY25 India pharma market turnover Mounjaro launch India Anti-diabetic segment pharma Indian domestic pharma unit growth IPM growth 2025 Cardiac segment growth pharma Glycomet GP sales 2025 Augmentin top-selling drug India Chronic disease drug sales India Indian pharmaceutical market FY25 Price-driven pharma growth Gastrointestinal therapy India Pharmarack pharma report Empagliflozin patent expiry India Top pharma therapies India Anti-obesity drug India

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-04-08 @ 18:41:29 (1 weeks ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 581 words

Reading Time: 4 minutes read

Sentences: 26 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 27727866

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 239 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions